RayKnowChina Research Map
Shortlist

RecruitingLymphomaPhase 2

Registered title, quoted from ClinicalTrials.gov

Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination.

An open trial on lymphoma, registered on ClinicalTrials.gov. Led by Chinese PLA General Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead (inferred)Chinese PLA General Hospital中国人民解放军总医院BeijingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07489989, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to 85 years; sex: all

    Registered eligibility fields

  2. Histologically or cytologically confirmed CD19 and/or CD22-positive large B-cell lymphoma (LBCL) according to the WHO 2016 classification, including diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBL), and related entities, with one of the following:

    Inclusion criterion 1

    High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements ("double-hit" or "triple-hit") confirmed by fluorescence in situ hybridization (FISH);

    Inclusion criterion 5

  3. Partial response (PR) after induction therapy with a standard first-line chemotherapy regimen (e.g., R-CHOP for 4-6 cycles); or

    Inclusion criterion 2

    Less than 50% tumor reduction or disease progression after ≥4 cycles of standardized chemotherapy;

    Inclusion criterion 13

    Relapse within 6 months after achieving CR with standard regimen;

    Inclusion criterion 14

    History of other malignancy, unless the patient has been disease-free and has received no antitumor therapy for at least 3 years (exceptions: non-melanoma skin cancer, and carcinoma in situ of the cervix, bladder, or breast).

    Exclusion criterion 11

  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.

    Inclusion criterion 19

  5. Hemoglobin (HGB) ≥60 g/L (transfusion permitted).

    Inclusion criterion 21

    Absolute neutrophil count (ANC) ≥1,000/μL and platelet count ≥45,000/μL.

    Inclusion criterion 22

    Total bilirubin (TBIL) ≤1.5 × upper limit of normal (ULN) (except for patients with Gilbert's syndrome);

    Inclusion criterion 24

    Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 × ULN;

    Inclusion criterion 25

    Serum creatinine (Cr) ≤1.5 × ULN **or** creatinine clearance (CCr) ≥60 mL/min (estimated by Cockcroft-Gault formula);

    Inclusion criterion 26

    Non-hematologic malignancy-related hepatic or renal impairment, including any of the following: ALT > 3 × ULN, AST > 3 × ULN, total bilirubin (TBIL) > 2 × ULN, or creatinine clearance < 30 mL/min.

    Exclusion criterion 5

  6. Female patients who are pregnant or breastfeeding (preconditioning chemotherapy regimen poses potential risk to the fetus or infant).

    Exclusion criterion 9

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07489989, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria

-

The patient must meet all of the following inclusion criteria:

  • Histologically or cytologically confirmed CD19 and/or CD22-positive large B-cell lymphoma (LBCL) according to the WHO 2016 classification, including diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBL), and related entities, with one of the following:
  • Partial response (PR) after induction therapy with a standard first-line chemotherapy regimen (e.g., R-CHOP for 4-6 cycles); or
  • Complete response (CR) after standard first-line induction therapy, but with high-risk features present at initial diagnosis.
  • Presence of high-risk features at initial diagnosis, defined as at least one of the following:
  • High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements ("double-hit" or "triple-hit") confirmed by fluorescence in situ hybridization (FISH);
  • High-grade B-cell lymphoma with 11q aberration (Burkitt-like lymphoma with 11q aberration);
  • International Prognostic Index (IPI) score of 2-5; age-adjusted IPI (aa-IPI) score of 2-3; or National Comprehensive Cancer Network-IPI (NCCN-IPI) score of 4-8;
  • CD5 positivity by immunohistochemistry;
  • Dual expression of MYC and BCL2 by immunohistochemistry (recommended thresholds: MYC ≥ 40% and BCL2 ≥ 50%);
  • TP53 mutation detected by gene sequencing;
  • Molecular subtype MCD or N1 by next-generation sequencing (NGS);
  • Relapsed/refractory B-cell lymphoma, meeting one of criteria ①-④ plus criterion ⑤:
  • Less than 50% tumor reduction or disease progression after ≥4 cycles of standardized chemotherapy;
  • Relapse within 6 months after achieving CR with standard regimen;
  • ≥2 relapses after CR;
  • Relapse after hematopoietic stem cell transplantation;
  • Must have received adequate prior therapy, including at least an anti-CD20 monoclonal antibody and anthracycline-containing combination chemotherapy.
  • Age 18 to 85 years, male or female.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
  • Expected survival of >3 months from the date of signing informed consent.
  • Hemoglobin (HGB) ≥60 g/L (transfusion permitted).
  • Absolute neutrophil count (ANC) ≥1,000/μL and platelet count ≥45,000/μL.
  • Adequate hepatic, renal, cardiac, and pulmonary function, meeting **all** of the following:
  • Total bilirubin (TBIL) ≤1.5 × upper limit of normal (ULN) (except for patients with Gilbert's syndrome);
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 × ULN;
  • Serum creatinine (Cr) ≤1.5 × ULN **or** creatinine clearance (CCr) ≥60 mL/min (estimated by Cockcroft-Gault formula);
  • Left ventricular ejection fraction (LVEF) ≥50% by echocardiogram (ECHO), with no pericardial effusion and no clinically significant arrhythmias;
  • Baseline oxygen saturation by pulse oximetry >92% on room air;
  • No clinically significant pleural effusion.

Exclusion Criteria:

  • Patients eligible for CAR-T cell immunotherapy must **NOT** meet any of the following exclusion criteria:
  • Prior treatment with any form of chimeric antigen receptor (CAR) T-cell therapy or other genetically modified T-cell therapy.
  • History of severe immediate-type hypersensitivity reaction to aminoglycoside antibiotics or other drugs.
  • Known history of human immunodeficiency virus (HIV) infection, active hepatitis B virus (HBV) infection, or any uncontrolled active systemic infection requiring intravenous antibiotics.

(Active HBV infection is defined as meeting **all** of the following: a) HBV DNA ≥ 2000 IU/mL; b) ALT ≥ 2 × upper limit of normal (ULN); c) hepatitis not attributable to other causes such as the underlying disease or medications. Patients with active HBV at initial diagnosis who achieve non-active HBV status after adequate anti-HBV treatment may be eligible under continued effective anti-HBV therapy.)

  • Non-hematologic malignancy-related hepatic or renal impairment, including any of the following: ALT > 3 × ULN, AST > 3 × ULN, total bilirubin (TBIL) > 2 × ULN, or creatinine clearance < 30 mL/min.
  • History of myocardial infarction, percutaneous coronary intervention (including coronary angioplasty or stenting), unstable angina, active arrhythmia, or other clinically significant cardiovascular disease within the past 12 months.
  • Any other serious medical condition that, in the opinion of the investigator, may interfere with the study treatment or increase risk to the patient (e.g., poorly controlled diabetes, active peptic ulcer disease, severe respiratory or circulatory disease, severe autoimmune disease, congenital immunodeficiency, uncontrolled severe infection, or other conditions with high risk of clinical deterioration).
  • History of severe immediate-type hypersensitivity reaction to any medication required during the treatment process, or history of severe allergy to biologics (including antibiotics).
  • Female patients who are pregnant or breastfeeding (preconditioning chemotherapy regimen poses potential risk to the fetus or infant).
  • In the opinion of the investigator, the patient is unlikely to comply with all required study visits, procedures, or long-term follow-up; has poor willingness or ability to participate and cooperate fully; or has insufficient compliance (as judged by the patient and/or family).
  • History of other malignancy, unless the patient has been disease-free and has received no antitumor therapy for at least 3 years (exceptions: non-melanoma skin cancer, and carcinoma in situ of the cervix, bladder, or breast).
  • Receipt of a live vaccine within 6 weeks prior to initiation of the preconditioning regimen.
  • Major surgery (excluding lymph node biopsy) within the past 14 days, or anticipated need for major surgery during the treatment period.
  • Any other serious physical or psychiatric illness, or clinically significant laboratory abnormality, that may increase the risk associated with study participation, interfere with the interpretation of study results, or render the patient unsuitable for participation in the opinion of the investigator.

Quoted from ClinicalTrials.gov, NCT07489989, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07489989, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07489989